For immediate release
Zagreb, 03 November 2005

PLIVA Announces Approval for Citalopram Hydrobromide Tablets

PLIVA d.d. announced today that PLIVA has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Citalopram Hydrobromide Tablets 10 mg, 20 mg, and 40 mg.

Citalopram Hydrobromide is the AB-rated generic equivalent of Forest Laboratories' Celexa, from a class of medications called selective serotonin reuptake inhibitors (SSRIs), used for the treatment of depression.

More information about PLIVA can be found at www.pliva.com.

For additional information, please contact:

Marija Mandić
Executive Director
Investor Relations & Corporate Communications
Tel: +385 1 6160 355, 6120 909
Fax: +385 1 6114 413
E-mail: Marija.Mandic@pliva.com